There is a version of cancer treatment most people picture without ever having sat through it: the chair, the pole, the bag, the hours. Somebody drove you. Somebody is in the waiting room. If you work, you took the day. If you live an hour out, you took more than the day. And if this is happening every few weeks, it isn't an appointment — it's a structure your whole life bends around.
Over the last several years, that structure started to loosen. Researchers figured out how to reformulate some complex biologics so they can be delivered as an injection under the skin instead of an infusion into a vein. What took most of a day can take minutes. What required a hospital outpatient department can sometimes happen at a clinic closer to home. The FDA reviewed these newer versions under their own applications, on the strength of their own clinical trials, and approved them as distinct medicines — because that is what they are.
The Centers for Medicare & Medicaid Services has proposed treating them as the same drug as the original IV product for pricing purposes.
Patients Rising supports Medicare drug price negotiation authority and we understand the goal behind this provision. The negotiation program should not be undermined by product changes designed primarily to restart the negotiation timeline. Closing that kind of loophole is a reasonable safeguard.
But the provision needs to distinguish between changes that merely extend a product's commercial life and innovations that meaningfully improve how patients receive treatment. A new formulation or delivery method can reduce hours in an infusion chair, eliminate repeated trips to a hospital, make treatment possible at home, or turn a burdensome therapy into something a patient can realistically manage alongside work and family.
As written, the provision risks treating those advances as though they were simply extensions of the original product. That matters not only for future innovation, but for where and how patients receive care. If a five-minute injection and an all-day infusion are effectively treated the same, the system may inadvertently preserve incentives for care to remain in more burdensome — and often more expensive — settings.
The goal should be straightforward: prevent manipulation of the negotiation timeline without discouraging innovations that make treatment meaningfully better for patients. That requires a scalpel, not a shotgun.
Here is what makes this round different from an ordinary disagreement over a proposed rule.
CMS floated essentially this same policy for the 2028 negotiation cycle. It drew serious pushback, and in final guidance last September the agency dropped it. Its own stated reason is worth sitting with: given the complexity and scope of the issue, CMS said it would need more time to develop objective policy criteria before finalizing anything like it. Then it signaled it would come back to the question for 2029.
That is the agency telling the public, in writing, that it did not yet know how to draw this line cleanly. It is now proposing to draw it anyway, and it has not shown the objective criteria it said it would need. We are not asking CMS to abandon a goal it just adopted. We are pointing out that CMS reached a conclusion about its own readiness twelve months ago, and nothing we can see has changed except the calendar.
The affordability math on this can invert, and that is the piece a price comparison never captures.
A patient pushed back into a hospital infusion setting pays in ways no spreadsheet tracks: the drive, the parking, the day of work gone, the caregiver's day of work gone, the facility fee that attaches to the hospital outpatient department, and coinsurance on provider-administered drugs that carries no annual cap the way Part D now does. The number on the government's ledger goes down. The number in the patient's life goes up. For a program built on the promise of affordability, that is not a rounding error — it is the promise running backward.
The people who feel it first are the people already carrying the most. Patients in rural and underserved communities who drive hours to reach specialty care. Working-age adults on Medicare through a disability, for whom a full-day appointment is lost income rather than an inconvenience. Homebound patients who cannot get anywhere without someone else's help. And this reaches well past oncology — the same logic touches neurologic and immune conditions, and the immunoglobulin therapies where the choice between infusion and subcutaneous delivery shapes whether treatment fits inside an ordinary week.
A bipartisan group of House members is pressing CMS on exactly this provision, asking the agency not to finalize it as written. We think they are right, and our own comments to CMS asked for the same three things.
Withdraw the fixed-combination modification in its current form, because it cannot reliably distinguish gaming from genuine, separately approved therapies that patients rely on. If CMS proceeds anyway, narrow it to target actual evasion and publish a patient-impact assessment first — covering site of care, treatment stability, and patients' total cost of care — rather than finalizing and finding out afterward. And keep the question of what counts as a distinct medicine grounded in clinical evidence and FDA review, not in pricing convenience.
None of that weakens Medicare's hand. A program that can tell a real advance from a cynical one is a stronger program, not a softer one.
A medicine is not only a molecule and a price. It is also how you get it, where you have to go, who has to come with you, and what the rest of your week looks like afterward. Those are not amenities. For a patient organizing life around treatment, they are most of the experience.
If Medicare's pricing rules cannot see that, they will keep producing decisions that look efficient on paper and land badly in people's lives. We would rather CMS see it now.
Has the way you receive treatment changed what your life looks like — for better or worse? Tell us. CMS is required by law to consider patient experience evidence, and stories like yours are how that record gets built.